

Sep 26, 2014

Dear Editor,

Please find enclosed the edited manuscript in Word format (file name: 13169-review.doc).

**Title:** Activity of novel regimen icotinib plus gemcitabine in metastatic pancreatic cancer patient: a case report

**Author:** *Jing Zhao, Hong Shen, Han-Guang Hu, Jian-Jin Huang*

**Name of Journal:** *World Journal of Gastroenterology*

**ESPS Manuscript NO:** 13169

The manuscript has been improved according to the suggestions of reviewers:

1 Format has been updated

2 Revision has been made according to the suggestions of the reviewer (which have been high light in red)

(1) According to the comments from Reviewer No. 1557283 “The authors should briefly summarize the tumor marker decrease, tumor shrinkage, and pain relief in the present patient and describe the efficacy of the Iconitib/gemcitabine in the Abstract”

**Answer:** We add the content about the changes of tumor marker, tumor size and the symptoms after the treatment in the abstract to emphasize the efficiency of the Iconitib/gemcitabine regimen.

(2) The reviewer No. 1557283 asked “Have the authors obtained the permission concerning the present treatment from the local ethical committee of the author’s institution?”

**Answer:** We had obtained the informed consent from the patient according to our hospital’s rules for the use of drug beyond the instruction. The copy of the informed consent for treatment with Icotinib would be attached at the end of this letter and is available for review by the editors and reviewers.

(3) The reviewer No. 1557283 asked “Why did not the patient undergo an endoscopic biliary drainage against the obstructive jaundice, e.g., ERBD stent, to continue the chemotherapeutic treatment?”

**Answer:** In fact, the patient accepted the treatment of endoscopic retrograde biliary drainage and the jaundice relieved. But the patient refused to accept further treatment and chose the best support care. We have added this content in the case report.

(4) The reviewer No. 1557283 asked “Was the present treatment covered with the Chinese insurance or with the authors’ institution?”

**Answer:** There are many types of medical insurances in China. Besides, the medical

catalogue is varied in different regions. For this patient, both icotinib and gemcitabine are covered by the local insurance but nimotuzumab or nab-paclitaxel is not. The regimen icotinib plus gemcitabine cost less than others. So this patient chose icotinib finally.

(5) The reviewer No. 1557283 suggested “The progression-free survival was similar to that of the gemcitabine alone as recently reported. The authors should focus on, for example, pain relief of the present regimen. “

**Answer:** We think in this case, the PFS was similar to the gemcitabine plus erlotinib regimen which have been approved by the FDA, a little better than gemcitabine alone. We had added some contents about the shrink of the tumor, relief of the pain in the discussion and emphasized more about the improvement of the life quality.

(6) The reviewer No. 3940 suggested “other combination therapies with EGFR blockade that should be explored from the literature in the discussion”

**Answer:** We had added the content about EGFR target therapy in the discussion section.

3 The language was edited by the AmEditor as your recommendation. They said they would send you the confirmation letter of editing service.

Thank you again for publishing our manuscript in the *World Journal of Gastroenterology*.

Sincerely yours,

Jing Zhao, MD

Department of Medical Oncology,

The Second Affiliated Hospital, Zhejiang University School of Medicine

88 Jie-Fang Road, Hangzhou, Zhejiang, China

Fax: +86-571-87767088

E-mail: [jing.zhao@163.com](mailto:jing.zhao@163.com)



浙江大学医学院附属第二医院

## 超说明书用药知情同意书

姓名: 沈兴水 性别: 男 年龄: 64岁 科室: 脾内 床位: 11-2 住院号: 02352636

临床诊断: 胰腺癌伴肝转移

涉及药品名称: 凯美纳 125mg 剂型: 口服 生产厂家: 浙江贝达药业

为了您健康利益的最大化, 我们针对您的病情, 建议超说明书使用上述药品。为了让您更好的理解, 我们进行如下善意告知:

1. 您的病情, 目前临床常规使用药品并不理想。在充分考虑药品不良反应、禁忌证、注意事项, 权衡患者的利益大于可能出现的危险, 我们认为被告知药品超说明书用法是您目前的最佳治疗方案。
2. 超说明书使用药品是医师、药师所享有的一种国际通行职业权利。根据患者目前的情况, 我们建议您采取此种治疗方案。
3. 该药品超说明书使用不是用于临床试验或科研目的, 否则您有权力拒绝接受。
4. 您有权力要求医师用通俗的语言对本知情同意书所载内容进行讲解, 在医师讲解后您有权力向其提问, 并应当得到科学、客观的回答。
5. 您已经被告知并理解, 使用被告知药品可能发生意外或不良反应, 如果发生医疗意外情况或不良反应, 医生将按有关诊治常规积极救治病人, 使您尽快康复。

如果发生医疗意外情况或上述不良反应, 医师将按有关诊治常规积极救治病人, 使您尽快地康复。

我声明, 经医生告知, 我已充分理解上述情况, 同意接受被告知药品超说明书用法, 并接受此种治疗可能发生的医疗风险。

患者或家属(监护人)签名: 沈兴水 与患者关系: 本人 日期: 2014-1-16 16:00

医师签名:

黄瑾

日期: 2014-1-16 14:00